Top 20 US Stock Deals: Pfizer Encounters Double Killing Lawsuit between Diet Drugs and COVID-19 Vaccine
不知道是谁
发表于 2023-12-2 10:53:29
3500
0
0
[The top 20 US stock turnover: Pfizer suffered a double battle between weight-loss drugs and COVID-19 vaccine litigation] The 12th Pfizer Pharmaceutical closed down 5.12%, the largest one-day decline since December 2021, with a turnover of 2.982 billion US dollars. On Thursday, Texas Attorney General Ken Paxton sued the company for misrepresenting the effectiveness of its COVID-19 vaccine. It is reported that Pfizer used misleading statistics to promote its COVID-19 vaccine and tried to "intimidate" anyone who questioned the product. The Texas Attorney General has demanded that the judge impose a fine of over $10 million and order a ban on Pfizer publicly promoting the effectiveness of its vaccine.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
- Pfizer and CR Pharma reach strategic partnership on four mature drugs
- Pfizer expects revenue of $61 billion to $64 billion in 2025, with an estimated $63.23 billion
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy